Leukemia - Table of Contents alert Volume 27 Issue 10

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 10 (October 2013) In this issue Reviews Original Articles Letters to the Editor Corrigenda Also new AOP Advertisement   Epigenetic biomarker development - an open call for proposals Deadline for submission of applications: November 7th, 2013, 17h00 CET Further information: www.blueprint-epigenome.eu    Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Nature Communications is ranked #3 in the Multidisciplinary Sciences with an Impact Factor of 10.015* Your research. Our reach. Together we make an impact.  nature.com/naturecommunications  *2012 Journal Citation Reports® (Thomson Reuters, 2013) Reviews Top Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia T Barbui, J Thiele, A M Vannucchi and A Tefferi Leukemia 2013 27: 1953-1958; advance online publication, March 7, 2013; 10.1038/leu.2013.74 Abstract | Full Text Review of health-related quality of life data in multiple myeloma patients treated with novel agents OPEN P Sonneveld, S G Verelst, P Lewis, V Gray-Schopfer, A Hutchings, A Nixon and M T Petrucci Leukemia 2013 27: 1959-1969; advance online publication, June 20, 2013; 10.1038/leu.2013.185 Abstract | Full Text Original Articles Top ACUTE LEUKEMIAS Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib M Huang, D Thomas, M X Li, W Feng, S M Chan, R Majeti and B S Mitchell Leukemia 2013 27: 1970-1980; advance online publication, July 23, 2013; 10.1038/leu.2013.222 Abstract | Full Text MYELODYSPLASIAS Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes S Mathis, N Chapuis, C Debord, A Rouquette, I Radford-Weiss, S Park, F Dreyfus, C Lacombe, M C Béné, O Kosmider, M Fontenay and V Bardet Leukemia 2013 27: 1981-1987; advance online publication, June 14, 2013; 10.1038/leu.2013.178 Abstract | Full Text Monosomal karyotype in MDS: explaining the poor prognosis? J Schanz, H Tüchler, F Solé, M Mallo, E Luño, J Cervera, J Grau, B Hildebrandt, M L Slovak, K Ohyashiki, C Steidl, C Fonatsch, M Pfeilstöcker, T Nösslinger, P Valent, A Giagounidis, C Aul, M Lübbert, R Stauder, O Krieger, M M Le Beau, J M Bennett, P Greenberg, U Germing and D Haase Leukemia 2013 27: 1988-1995; advance online publication, June 21, 2013; 10.1038/leu.2013.187 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target J G Harb, P Neviani, B J Chyla, J J Ellis, G J Ferenchak, J J Oaks, C J Walker, P Hokland, D C Roy, M A Caligiuri, G Marcucci, C S Huettner and D Perrotti Leukemia 2013 27: 1996-2005; advance online publication, May 14, 2013; 10.1038/leu.2013.151 Abstract | Full Text Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors O Kollet, Y Vagima, G D'Uva, K Golan, J Canaani, T Itkin, S Gur-Cohen, A Kalinkovich, G Caglio, C Medaglia, A Ludin, K Lapid, E Shezen, A Neufeld-Cohen, D Varol, A Chen and T Lapidot Leukemia 2013 27: 2006-2015; advance online publication, May 17, 2013; 10.1038/leu.2013.154 Abstract | Full Text The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib V S Hoffmann, M Baccarani, D Lindoerfer, F Castagnetti, A Turkina, A Zaritsky, A Hellmann, W Prejzner, J-L Steegmann, J Mayer, K Indrak, A Colita, G Rosti and M Pfirrmann Leukemia 2013 27: 2016-2022; advance online publication, June 11, 2013; 10.1038/leu.2013.171 Abstract | Full Text STEM CELLS A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia K H Metzeler, K Maharry, J Kohlschmidt, S Volinia, K Mrózek, H Becker, D Nicolet, S P Whitman, J H Mendler, S Schwind, A-K Eisfeld, Y-Z Wu, B L Powell, T H Carter, M Wetzler, J E Kolitz, M R Baer, A J Carroll, R M Stone, M A Caligiuri, G Marcucci and C D Bloomfield Leukemia 2013 27: 2023-2031; advance online publication, June 14, 2013; 10.1038/leu.2013.181 Abstract | Full Text MINIMAL RESIDUAL DISEASE Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study OPEN J V Jovanovic, A Ivey, A M Vannucchi, E Lippert, E Oppliger Leibundgut, B Cassinat, N Pallisgaard, N Maroc, S Hermouet, G Nickless, P Guglielmelli, B A van der Reijden, J H Jansen, T Alpermann, S Schnittger, A Bench, K Tobal, B Wilkins, K Cuthill, D McLornan, K Yeoman, S Akiki, J Bryon, S Jeffries, A Jones, M J Percy, S Schwemmers, A Gruender, T W Kelley, S Reading, A Pancrazzi, M F McMullin, H L Pahl, N C P Cross, C N Harrison, J T Prchal, C Chomienne, J J Kiladjian, T Barbui and D Grimwade Leukemia 2013 27: 2032-2039; advance online publication, July 17, 2013; 10.1038/leu.2013.219 Abstract | Full Text NORMAL HEMOPOIESIS mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells F Guo, J Li, W Du, S Zhang, M O'Connor, G Thomas, S Kozma, B Zingarelli, Q Pang and Y Zheng Leukemia 2013 27: 2040-2046; advance online publication, March 29, 2013; 10.1038/leu.2013.93 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia F Hariri, M Arguello, L Volpon, B Culjkovic-Kraljacic, T H Nielsen, J Hiscott, K K Mann and K L B Borden Leukemia 2013 27: 2047-2055; advance online publication, March 7, 2013; 10.1038/leu.2013.73 Abstract | Full Text MYELOMA A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control B Paiva, M-B Vídriales, L Rosiñol, J Martínez-López, M-V Mateos, E M Ocio, M-Á Montalbán, L Cordón, N C Gutiérrez, L Corchete, A Oriol, M-J Terol, M-A Echeveste, R De Paz, F De Arriba, L Palomera, J de la Rubia, J Díaz-Mediavilla, M Granell, A Gorosquieta, A Alegre, A Orfao, J-J Lahuerta, J Bladé and J F San Miguel on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group Leukemia 2013 27: 2056-2061; advance online publication, June 7, 2013; 10.1038/leu.2013.166 Abstract | Full Text Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma G Srivastava, V Rana, M Q Lacy, F K Buadi, S R Hayman, A Dispenzieri, M A Gertz, D Dingli, S Zeldenrust, S Russell, A McCurdy, P Kapoor, R Kyle, S V Rajkumar and S Kumar Leukemia 2013 27: 2062-2066; advance online publication, May 7, 2013; 10.1038/leu.2013.143 Abstract | Full Text Letters to the Editor Top Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity P L Bergsagel and W M Kuehl Leukemia 2013 27: 2067-2068; advance online publication, May 6, 2013; 10.1038/leu.2013.139 Full Text Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia F Stölzel, U Platzbecker, B Mohr, C Röllig, J M Middeke, C Thiede, M Füssel, M Hänel, M Schaich, G Ehninger, J Schetelig and M Bornhäuser Leukemia 2013 27: 2068-2072; advance online publication, May 7, 2013; 10.1038/leu.2013.142 Full Text SETBP1 mutation analysis in 944 patients with MDS and AML F Thol, K J Suchanek, C Koenecke, M Stadler, U Platzbecker, C Thiede, T Schroeder, G Kobbe, S Kade, P Löffeld, S Banihosseini, G Bug, O Ottmann, W-K Hofmann, J Krauter, N Kröger, A Ganser and M Heuser Leukemia 2013 27: 2072-2075; advance online publication, May 7, 2013; 10.1038/leu.2013.145 Full Text Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib H A F Stessman, A Mansoor, F Zhan, S Janz, M A Linden, L B Baughn and B Van Ness Leukemia 2013 27: 2075-2077; advance online publication, May 14, 2013; 10.1038/leu.2013.148 Full Text NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes D M Murphy, R Bejar, K Stevenson, D Neuberg, Y Shi, C Cubrich, K Richardson, P Eastlake, G Garcia-Manero, H Kantarjian, B L Ebert and G Mike Makrigiorgos Leukemia 2013 27: 2077-2081; advance online publication, May 27, 2013; 10.1038/leu.2013.160 Full Text Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML K Takahashi, E Jabbour, X Wang, R Luthra, C Bueso-Ramos, K Patel, S Pierce, H Yang, Y Wei, N Daver, S Faderl, F Ravandi, Z Estrov, J Cortes, H Kantarjian and G Garcia-Manero Leukemia 2013 27: 2081-2083; advance online publication, June 7, 2013; 10.1038/leu.2013.165 Full Text Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis T Barbui, A Carobbio, G Finazzi, P Guglielmelli, S Salmoiraghi, V Rosti, A Rambaldi, A M Vannucchi and G Barosi Leukemia 2013 27: 2084-2086; advance online publication, July 5, 2013; 10.1038/leu.2013.207 Full Text The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo OPEN E Todisco, F Ciceri, E Oldani, C Boschini, C Micò, M T VanLint, I Donnini, F Patriarca, P E Alessandrino, F Bonifazi, W Arcese, W Barberi, P Marenco, E Terruzzi, S Cortelazzo, S Santarone, A Proia, P Corradini, E Tagliaferri, S Falcioni, G Irrera, L Dallanegra, L Castagna, A Santoro, A Camboni, N Sacchi, A Bosi, A Bacigalupo and A Rambaldi Leukemia 2013 27: 2086-2091; advance online publication, July 9, 2013; 10.1038/leu.2013.208 Full Text Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis A Pardanani, D Chen, R A Abdelrahman, K K Reichard, D Zblewski, A J Wood, R F McClure, J H Butterfield, C A Hanson and A Tefferi Leukemia 2013 27: 2091-2094; advance online publication, July 30, 2013; 10.1038/leu.2013.227 Full Text CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway R C Prins, R T Burke, J W Tyner, B J Druker, M M Loriaux and S E Spurgeon Leukemia 2013 27: 2094-2096; advance online publication, July 31, 2013; 10.1038/leu.2013.228 Full Text γ-Catenin is expressed throughout normal human hematopoietic development and is required for normal PU.1-dependent monocyte differentiation R G Morgan, K Liddiard, L Pearn, S L Pumford, A K Burnett, R L Darley and A Tonks Leukemia 2013 27: 2096-2100; advance online publication, April 2, 2013; 10.1038/leu.2013.96 Full Text SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML OPEN R R Laborde, M M Patnaik, T L Lasho, C M Finke, C A Hanson, R A Knudson, R P Ketterling, A Pardanani and A Tefferi Leukemia 2013 27: 2100-2102; advance online publication, April 5, 2013; 10.1038/leu.2013.97 Full Text Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial H Zimmermann, S Choquet, J Moore, G Salles, F Morschhauser, T Lamy, A Jaccard, H A Horst, M Leithäuser, U Dührsen, P Reinke, Y Lebranchu, R Neuhaus, H Lehmkuhl, C Tarella, P Schlattmann, H Riess, V Leblond and R U Trappe for the German PTLD study group and the European PTLD Network Leukemia 2013 27: 2102-2105; advance online publication, April 15, 2013; 10.1038/leu.2013.110 Full Text Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients D M Ross, M O'Hely, P A Bartley, P Dang, J Score, J M Goyne, M Sobrinho-Simoes, N C P Cross, J V Melo, T P Speed, T P Hughes and A A Morley Leukemia 2013 27: 2105-2107; advance online publication, April 16, 2013; 10.1038/leu.2013.116 Full Text Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes H I Suzuki, H Matsuyama, M Noguchi, T Yao, N Komatsu, H Mano, K Sugimoto and K Miyazono Leukemia 2013 27: 2107-2111; advance online publication, April 18, 2013; 10.1038/leu.2013.121 Full Text Corrigenda Top A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control B Paiva, M-B Vídriales, L Rosiñol, J Martínez-López, M-V Mateos, E M Ocio, M-Á Montalbán, L Cordón, N C Gutiérrez, L Corchete, A Oriol, M-J Terol, M-A Echeveste, R De Paz, F De Arriba, L Palomera, J de la Rubia, J Díaz-Mediavilla, M Granell, A Gorosquieta, A Alegre, A Orfao, J-J Lahuerta, J Bladé and J F San Miguel on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group Leukemia 2013 27: 2112; 10.1038/leu.2013.213 Full Text Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes M M Patnaik, E Padron, R R LaBorde, T L Lasho, C M Finke, C A Hanson, J M Hodnefield, R A Knudson, R P Ketterling, A Al-kali, A Pardanani, N A Ali, R S Komrokji and A Tefferi Leukemia 2013 27: 2112; 10.1038/leu.2013.229 Full Text Advertisement New Rising Impact Factor Leukemia celebrates a new Impact Factor of 10.164 and the journal is now ranked No. 2 in Hemtology and No. 8 in Oncology. Thank you for your support of the Leukemia. Read a free review: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia *2012 Journal Citation Reports® (Thomson Reuters, 2013)    Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.